The average one-year price target for Travere Therapeutics (NasdaqGM:TVTX) has been revised to $42.33 / share. This is an ...
Ligand is increasing its 2025 full year financial guidance. The Company now expects total core revenue of $225 million to $235 million (previously $200 million to $225 million) and core adjusted ...
Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' ...
Investor's Business Daily on MSN
Stock Market Today: Dow Jones Climbs Off Lows As Nvidia Jumps; Micron, Palantir Lead Nasdaq (Live Coverage)
The Dow Jones Industrial Average was well off session lows along with the other major indexes Friday as stocks managed to ...
The S&P 1500 Health Care Index gained 1.9% in September, underperforming the S&P 500, which advanced 3.7%. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results